CYRX - Cryoport, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
12.90
-0.33 (-2.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.23
Open12.83
Bid12.55 x 800
Ask16.00 x 1200
Day's Range12.57 - 13.15
52 Week Range6.02 - 16.88
Volume276,749
Avg. Volume485,990
Market Cap368.549M
Beta2.11
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateJun 29, 2017 - Jun 30, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.25
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of CYRX earnings conference call or presentation 9-Aug-18 8:30pm GMT

    Q2 2018 Cryoport Inc Earnings Call

  • Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma
    PR Newswire7 days ago

    Cryoport Revenue Grows 59% for Second Quarter 2018; 73% in Biopharma

    Revenue from Approved CAR-T Therapies Continues to Ramp Record 258 Clinical Trials Now Supported by Cryoport, with 34 Programs in Phase III IRVINE, Calif. , Aug. 9, 2018 /PRNewswire/ -- Cryoport, Inc. ...

  • Cryoport Launches CryoStork℠ Insurance to Support IVF Logistics Solutions
    PR Newswire9 days ago

    Cryoport Launches CryoStork℠ Insurance to Support IVF Logistics Solutions

    IRVINE, Calif., Aug. 7, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature-controlled logistics company dedicated to the life sciences industry, today announced the upcoming launch of CryoStork℠ Insurance, which is designed to better serve intended parents and is also in response to the rise in demand for assisted reproductive medicine. With many couples struggling with infertility and approximately 6.7 million women in the U.S. alone unable to bear a child as reported by the American Society for Reproductive Medicine (ASRM), Cryoport is proud to now expand its offerings for the reproductive medicine market to include insurance options. CryoStork℠ Insurance will be offered exclusively to Cryoport clients and to the patients at the more than 400 clinics working with Cryoport.

  • Cryoport to Report Second Quarter 2018 Financial Results on August 9th, 2018
    PR Newswire15 days ago

    Cryoport to Report Second Quarter 2018 Financial Results on August 9th, 2018

    IRVINE, Calif. , Aug. 1, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company ...

  • Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market
    PR Newswirelast month

    Cryoport Partners with World Courier to Provide Best-In-Class Logistics Platform for Global Cell and Gene Therapy Market

    IRVINE, Calif., July 16, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), today announced that World Courier, a part of AmerisourceBergen, will integrate Cryoport's full suite of temperature-controlled solutions into its global network.  This integrated platform offers complete Chain of Compliance™ solutions for biopharmaceutical companies, ensuring full traceability of equipment, processes, and handling of cell and gene therapies while in transit. This will result in an offering of Cryoport's Chain of Compliance™ solutions to World Courier clients.

  • Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday
    PR Newswire2 months ago

    Cryoport Delivers Biological Samples for International Space Station; Rocket Launched Today Arrives at International Space Station on Monday

    IRVINE, Calif., June 29, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, announced that biological samples transported by Cryoport were launched today at 5:42 am EDT on SpaceX's Falcon 9 rocket which took off from Cape Canaveral in Florida to the International Space Station (ISS). On May 25, 2018, Cryoport managed the transportation of biological samples, specifically isolated primary human mononuclear cells from blood donors, from the University of Zurich to the Kennedy Space Center.

  • When Should You Buy Cryoport Inc (NASDAQ:CYRX)?
    Simply Wall St.2 months ago

    When Should You Buy Cryoport Inc (NASDAQ:CYRX)?

    Cryoport Inc (NASDAQ:CYRX), a medical equipment company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months. AsRead More...

  • Cryoport Set to Join Russell 3000 Index and Russell 2000 Index
    PR Newswire2 months ago

    Cryoport Set to Join Russell 3000 Index and Russell 2000 Index

    IRVINE, Calif., June 11, 2018 /PRNewswire/ -- Cryoport, Inc. (CYRX) (NASDAQ:CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences industry, today announced it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after the US market opens on June 25th, according to a preliminary list of additions posted June 8th. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11th, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • ACCESSWIRE3 months ago

    Free Research Report as Bemis’ Sales Rose 4% and Non-GAAP EPS Jumped 9%

    LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want access to our free earnings report on Bemis Co., Inc. (NYSE: BMS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BMS. The Company reported its first quarter fiscal 2018 operating and financial results on April 26, 2018. The packaging Company outperformed top- and bottom-line expectations, and re-affirmed its outlook for FY18.

  • Zacks Small Cap Research3 months ago

    CYRX: Q1 2018: Initial Meaningful Commercial Revenue in Q1, Could Ramp Quickly

    Cryoport (CYRX) reported Q1 financial results and provided a business update. Noteworthy is that contribution from commercial revenue (i.e. Q1 marked the first period in which commercialized support made a meaningful revenue contribution – accounting for approximately 8% of total revenue and 10% of biopharma revenue.

  • Cryoport Revenue Grows 48% for First Quarter; 62% in Biopharma
    PR Newswire3 months ago

    Cryoport Revenue Grows 48% for First Quarter; 62% in Biopharma

    Cryoport Commercial Revenue from Approved Therapies Grow; Clinical Support Programs Rise to Record Total of 236 Trials with 31 Programs in Phase III IRVINE, Calif. , May 3, 2018 /PRNewswire/ -- Cryoport, ...

  • Cryoport to Report First Quarter 2018 Financial Results on May 3rd, 2018
    PR Newswire4 months ago

    Cryoport to Report First Quarter 2018 Financial Results on May 3rd, 2018

    IRVINE, Calif. , April 23, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the global leader in temperature-controlled logistics dedicated ...

  • ACCESSWIRE5 months ago

    Free Post Earnings Research Report: Sealed Air’s Quarterly Revenues Advanced 11.48%; EPS Increased 16%

    Stock Monitor: Cryoport Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 13, 2018 / Active-Investors.com has just released a free earnings report on Sealed Air Corp. (NYSE: SEE ). If you want access ...

  • Zacks Small Cap Research5 months ago

    CYRX: Q4 2017: Close Of Record-Setting Year, Commercial Pipeline Represents Next Revenue Inflection

    By Brian Marckx, CFA NASDAQ:CYRX Cryoport (NASDAQ:CYRX) reported Q4 financial results and provided a business update.  Revenue came in moderately below our number – most of which we think relates to difference ...

  • Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017
    PR Newswire5 months ago

    Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017

    Cryoport added 85 new biopharma trials in 2017 Cryoport now supports a total of 214 trials with 26 Phase III clinical trials IRVINE, Calif. , March 6, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ...

  • ACCESSWIRE5 months ago

    CryoPort, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 6, 2018 / CryoPort, Inc. (NASDAQ: CYRX ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018 at 4:30 PM Eastern Time. To listen ...

  • When Can We Expect A Profit From Cryoport Inc (NASDAQ:CYRX)?
    Simply Wall St.5 months ago

    When Can We Expect A Profit From Cryoport Inc (NASDAQ:CYRX)?

    Cryoport Inc’s (NASDAQ:CYRX): CryoPort, Inc. provides cryogenic logistics solutions to the life sciences industry in the United States, Europe, Asia, and internationally. The US$234.47M market-cap company’s loss lessens since itRead More...

  • Business Wire6 months ago

    McKesson Specialty Health and Cryoport Collaborate to Bolster Logistics Services to Support Commercialization of Cell and Gene Therapies

    McKesson Specialty Health, a division of McKesson Corporation, announced a strategic collaboration with Cryoport, Inc. designed to further strengthen its robust logistics services to support the delivery of cell and gene therapies to patients at the point of care.

  • Cryoport to Report Fourth Quarter and Fiscal Year 2017 Financial Results on March 6th, 2018
    PR Newswire6 months ago

    Cryoport to Report Fourth Quarter and Fiscal Year 2017 Financial Results on March 6th, 2018

    IRVINE, Calif. , Feb. 20, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the world's leading temperature controlled logistics company ...

  • Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial
    PR Newswire6 months ago

    Cryoport to Provide DiscGenics with Cutting Edge Cold Chain Logistics Support for its Phase 1/2 Trial

    IRVINE, Calif., Feb. 15, 2018 /PRNewswire/ -- Cryoport, Inc. (CYRX), (CYRXW) ("Cryoport" or the "Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, today announced it has been selected by DiscGenics to provide logistics support to its multicenter, first-in-human study to evaluate the safety and preliminary efficacy of IDCT, its allogeneic injectable cell therapy, in patients with single level, symptomatic lumbar intervertebral disc degeneration. Cryoport's comprehensive, temperature-controlled logistics support services will include outbound logistics for DiscGenics' Clinical Phase 1/2 trial of IDCT to clinics in both the United States, and eventually Japan.

  • Cryoport To Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis
    PR Newswire6 months ago

    Cryoport To Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis

    IRVINE, Calif. , Feb. 5, 2018 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading temperature controlled logistics company dedicated to the life sciences industry, ...

  • Capital Cube8 months ago

    ETFs with exposure to CryoPort, Inc. : December 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire8 months ago

    The Cryoport Biotech Activity Index Decreases 7.1% In Third Quarter of 2017; While the Total Number of Clinical Trials Increases to 934 Worldwide

    In Q3 2017 approximately $1.85 billion was invested in the development of regenerative therapies and clinical trials advanced to 934. IRVINE, Calif., Dec. 18, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM"), which quantifies the activity in the development and clinical trials of regenerative therapies in the United States, decreased 7.1% to 222 in the third quarter of 2017. The CoBRA Index SM acts as a means by which investors, the media and industry participants can evaluate investment in the space by viewing activity in clinical trials.

  • Capital Cube9 months ago

    ETFs with exposure to CryoPort, Inc. : November 24, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube9 months ago

    ETFs with exposure to CryoPort, Inc. : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CryoPort, Inc. Here are 5 ETFs with the largest exposure to CYRX-US. Comparing the performance and risk of CryoPort, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)